文献速递肝病

来迪派韦-索磷布韦治疗3至<6岁慢性丙肝儿童12周

Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
PubMed 文献 · Hepatology · 2019-08-19

一项开放标签研究评估来迪派韦-索磷布韦颗粒剂治疗3至<6岁慢性HCV感染儿童(基因1型33例、4型1例)12周的安全性和疗效,按体重给药。SVR12达97%(33/34),最常见不良事件为呕吐、咳嗽和发热,无严重不良事件。

要点

  • 3至<6岁慢性HCV儿童按体重接受来迪派韦-索磷布韦颗粒剂12周,SVR12为97%(33/34)。
  • 最常见不良事件为呕吐(24%)、咳嗽(21%)和发热(21%),无严重不良事件。
  • 1例3岁患者因不良事件「药物味道异常」在第5天停药,未达到SVR12。

核心结论

  • 来迪派韦-索磷布韦在3至<6岁慢性HCV感染儿童中耐受性良好且高度有效。

研究设计与样本

  • 开放标签研究,纳入3至<6岁慢性HCV基因1型(n=33)或4型(n=1)儿童,共34例,按体重接受来迪派韦-索磷布韦颗粒剂治疗12周。

主要发现

  • SVR12在97%的患者中达成(33/34);未达成SVR12的1例为3岁患者,因不良事件「药物味道异常」在第5天停药。
  • 最常见不良事件为呕吐(24%的患者)、咳嗽(21%)和发热(21%);无患者发生严重不良事件。
  • 对13例可评估患者进行密集药代动力学分析,确认所选剂量适当。

关键数值与推荐

  • 体重<17 kg者使用33.75 mg/150 mg,体重≥17 kg者使用45 mg/200 mg,治疗12周。
  • 10例患者(29%)体重<17 kg。
  • 所有患者均为围产期传播感染且为初治,无已知肝硬化。

临床怎么用

  • 对于3至<6岁慢性HCV基因1型或4型感染儿童,可考虑按体重给予来迪派韦-索磷布韦颗粒剂治疗12周。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct-acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir-sofosbuvir in HCV-infected children aged 3 to <6 years. In an open-label study, patients 3 to <6 years old chronically infected with HCV genotype 1 (n = 33) or 4 (n = 1) received weight-based doses of combined ledipasvir-sofosbuvir as granules (33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks. The primary endpoint was sustained virological response 12 weeks after treatment (SVR12). For the first 14 patients, intensive pharmacokinetic sampling was done on day 10 of treatment. All patients had been infected through perinatal transmission and were treatment naïve. No patients had known cirrhosis. Ten patients (29%) weighed <17 kg. SVR12 was achieved in 97% of patients (33 of 34); the patient who did not achieve SVR12 was 3 years old and discontinued treatment after 5 days because of an adverse event "abnormal drug taste." The most common adverse events were vomiting (24% of patients), cough (21%), and pyrexia (21%). No patients experienced a serious adverse event. Intensive pharmacokinetic analysis of 13 patients for whom data were evaluable confirmed that the doses selected were appropriate. Conclusion: Ledipasvir-sofosbuvir was well tolerated and highly effective in children 3 to <6 years old with chronic HCV infection.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. Hepatology. 2019. PMID: 31220349. doi:10.1002/hep.30830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。